Medical experts emphasize that these changes are typically temporary and may relate to the body's adjustment to new eating patterns and weight loss occurring as an impact of the medications T-2 diabetes management
Donnarumma E, Kohlhaas M, Vimont E, Kornobis E, Chaze T, Gianetto QG, et al
This approval offers adults with obesity or overweight a beneficial new treatment option to incorporate into a weight management program, said John Sharretts, M.D., deputy director of the Division of Diabetes, Lipid Disorders, and Obesity in the FDAs Center for Drug Evaluation and Research
A steady and well-rounded approach is key to achieving long-term success
July 2024: A new study, published on July 3, 2024, indicates patients taking semaglutide such as Wegovy may face an increased risk of serious eye injuries, including nonarteritic anterior ischemic optic neuropathy (NAION)